BioSpace News Archive

Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the closing of its upsized public offering of 6,900,00

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will host a live webcast presentation on Monday, December 14, 2020 at 8:00 a.m. ET to provide clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110. The presentation will include upda

HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,910,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $11.75 and the pub

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. The stock options are exercisable at a price of $39.77 per share, the closing price of Albireo’s common stock on December 9, 2020, the grant date, and were granted as inducements material to the em

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 6,250,000 shares of its common stock, which includes the exercise in

U.S. Government Exercises 1 st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate Total of 200 million doses ordered by the U.S government to date Additional doses ordered today will be delivered in Q2 2021 U.S. government retains option to purchase up to an additional 300 million doses

Envision Healthcare, one of the country’s leading medical groups, announced today new additions and transitions within its leadership team. “As a leading national medical group, we are proud to build a team of talented, innovative individuals who make our business better,” said President and Chief Executive Officer Jim Rechtin. “Our senior leaders are focused on building a strong and nimble organization that can ta

VIVUS, Inc. (the “ Company ”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “ Bankruptcy Court ”) on its Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (the “ Plan ”). The Bankruptcy Court approved the disclosure statement and solicitation procedures and con

Aerpio Pharmaceuticals, Inc.(Aerpio) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of T

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 10, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering an aggregate of 3,000 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted o